Abstract
Accumulating data suggest that bone-seeking radiophar-maceuticals can be used to treat prostate cancer bone metastasis and improve the clinical outcome of patients with advanced prostate cancer. It remains to be elucidated whether radiopharmaceuticals enhance the disruption of the onco-niche or the eradication of micrometastatic cells in the bone marrow. The purpose of this review is to investigate the role of bone-targeted radioisotope therapy in the setting of multimodality therapy for advanced prostate cancer. We examine available data and evaluate whether dose escalation, newer generations, or repeated dosing of radiopharmaceuticals enhance their antitumor effects and whether their combination with hormone ablative therapy, chemotherapy, or novel targeted therapy can improve clinical efficacy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 341-351 |
| Number of pages | 11 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 8 |
| Issue number | 5 |
| State | Published - May 2010 |
Keywords
- Advanced prostate cancer
- Bone metastases
- Onco-niche
- Radiopharmaceuticals
ASJC Scopus subject areas
- Hematology
- Oncology